Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | PBRM1 inact mut VHL loss |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
PBRM1 inact mut VHL loss | clear cell renal cell carcinoma | sensitive | Belzutifan + PRT1419 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of PRT1419 and Welireg (belzutifan) inhibited tumor growth of a clear cell renal cell carcinoma cell line xenograft model harboring an inactivating PBRM1 mutation and with loss of VHL (PMID: 38371625). | 38371625 |